ストックスクリーナーアプリを入手
23.12
3.47%
-0.83
アフターアワーズ：
23.86
0.74
+3.20%
前日終値:
$23.95
開ける：
$24.4
24時間の取引高:
5.32M
Relative Volume:
2.84
時価総額：
$2.35B
収益：
$139.74M
当期純損益:
$-79.99M
株価収益率:
-22.76
EPS:
-1.0157
ネットキャッシュフロー:
$-360.05M
1週間 パフォーマンス:
-8.69%
1か月 パフォーマンス:
-21.92%
6か月 パフォーマンス:
+0.13%
1年 パフォーマンス:
-0.43%
1日の値動き範囲:
$23.07
$25.34
1週間の範囲:
$23.07
$25.98
52週間の値動き範囲:
$13.53
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
名前
Beam Therapeutics Inc
セクター
電話
857-327-8775
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
23.12 | 2.44B | 139.74M | -79.99M | -360.05M | -1.0157 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-20 | 開始されました | Canaccord Genuity | Buy |
| 2025-10-09 | 開始されました | Jefferies | Buy |
| 2025-03-28 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-03-10 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-08 | ダウングレード | Jefferies | Buy → Hold |
| 2023-10-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 開始されました | Citigroup | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-01-05 | 開始されました | Guggenheim | Buy |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-09-24 | 再開されました | Stifel | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Redburn | Buy |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 開始されました | Wells Fargo | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-08-05 | 開始されました | William Blair | Outperform |
| 2020-03-02 | 開始されました | Barclays | Overweight |
| 2020-03-02 | 開始されました | JP Morgan | Overweight |
| 2020-03-02 | 開始されました | Jefferies | Buy |
| 2020-03-02 | 開始されました | Wedbush | Outperform |
すべてを表示
Beam Therapeutics Inc (BEAM) 最新ニュース
Beam To Extend Current Trial For Pivotal BEAM-302 Development - Citeline News & Insights
RBC Capital reiterates Beam Therapeutics stock rating on A1AT data By Investing.com - Investing.com Australia
Leerink raises Beam Therapeutics stock price target on AATD data - Investing.com
Beam Therapeutics’ BEAM-302 Hits Protective AAT Levels in AATD; 60 mg Picked for Pivotal in H2 2026 - MarketBeat
Clear Street reiterates Beam Therapeutics stock rating on AATD data - Investing.com UK
William Blair reiterates Beam Therapeutics stock rating on positive trial data - Investing.com
Beam Therapeutics (BEAM) Sees Positive Data, Analyst Reaffirms B - GuruFocus
RBC Capital reiterates Beam Therapeutics stock rating on A1AT data - Investing.com
Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels - Benzinga
Beam Therapeutics (BEAM) Advances Gene Therapy for Accelerated A - GuruFocus
Beam to move gene-editing drug in pivotal study (BEAM:NASDAQ) - Seeking Alpha
Beam Therapeutics (BEAM) Shares Promising BEAM-302 Trial Data - GuruFocus
Beam Therapeutics Says It Advances BEAM-302 to Pivotal Stage With 60 mg Dose Selection - marketscreener.com
Why Did BEAM Stock Jump 10% In Pre-Market Today? - Stocktwits
Beam Therapeutics stock jumps on positive trial data By Investing.com - Investing.com Australia
BEAM: BEAM-302 at 60 mg delivers durable, functional AAT restoration and strong safety in AATD - TradingView
Beam Therapeutics Reports Positive Phase 1/2 Trial Results for BEAM-302 in Alpha-1 Antitrypsin Deficiency, Selecting 60 mg as Optimal Dose for Pivotal Development - Quiver Quantitative
Beam Therapeutics selects 60 mg dose for AATD gene therapy trial - Investing.com
One gene-editing dose kept patients above protective protein levels - Stock Titan
Guidance Update: How does Beam Therapeutics Inc perform in inflationary periodsQuarterly Trade Report & Low Drawdown Trading Strategies - baoquankhu1.vn
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Beam Therapeutics Inc. (BEAM) reports Q4 loss, beats revenue estimates - MSN
Aug Retail: Is Beam Therapeutics Inc in a long term uptrend2026 Market Overview & Pattern Based Trade Signal System - baoquankhu1.vn
Sickle Cell Disease Market: Investment-Ready Growth Trends to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics Inc., Graphite Bio, Roche, Quercis - Barchart.com
Best CRISPR Companies for 2026 and How to Invest in Them - The Motley Fool
(BEAM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS) - The Globe and Mail
Farallon Capital Management LLC Purchases 50,000 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Inc. $BEAM is Casdin Capital LLC's 9th Largest Position - MarketBeat
Integral Health Asset Management LLC Decreases Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
BEAM Stock Price, Quote & Chart | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - The Globe and Mail
H.C. Wainwright Keeps Their Buy Rating on Beam Therapeutics (BEAM) - The Globe and Mail
BEAM.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
JonesTrading Reduces the PT on Beam Therapeutics (BEAM), Keeps a Buy Rating - MSN
Liquidity Mapping Around (BEAM) Price Events - Stock Traders Daily
According to a document submitted to the U.S. Securities and Exchange Commission (SEC) on March 2, Beam Therapeutics Inc. and Bio Palette have jointly decided to terminate the licensing agreement signed by both parties on March 27, 2019. - Bitget
Beam Therapeutics Restructures Base-Editing Licensing After Bio Palette Exit - TipRanks
Beam Therapeutics Inc. Terminates License Agreement with Bio Palette Co., Ltd - marketscreener.com
HC Wainwright Predicts Weaker Earnings for Beam Therapeutics - MarketBeat
JPMorgan Chase & Co. Trims Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
ARK Investment Boosts Stake in Beam Therapeutics - National Today
Amova Asset Management Americas Inc. Buys 103,939 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
ARK Investment Management LLC Increases Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Earnings Call Highlights PKU Pivot - TipRanks
What is HC Wainwright's Forecast for BEAM Q1 Earnings? - MarketBeat
Mintz Advises Sixth Street On $500 Million Strategic Financing Facility With Beam Therapeutics - Mondaq
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) - mx.advfn.com
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com
Contrarius Group Holdings Ltd Buys Shares of 1,533,269 Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Inc (BEAM) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):